Shanghai Henlius Biotech, Inc. (HKG:2696)

Shanghai Henlius Biotech Revenue

In the year 2025, Shanghai Henlius Biotech had annual revenue of 6.67B CNY with 16.46% growth. Shanghai Henlius Biotech had revenue of 3.85B in the half year ending December 31, 2025, with 32.91% growth.

• Revenue: 6.67B CNY
• Revenue Growth: +16.46%
• P/S Ratio: 4.36
• Revenue / Employee: 1.77M CNY
• Employees: 3,762
• Market Cap: 32.37B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	6.67B	942.18M	16.46%
Dec 31, 2024	5.72B	329.54M	6.11%
Dec 31, 2023	5.39B	2.18B	67.82%
Dec 31, 2022	3.21B	1.53B	91.07%
Dec 31, 2021	1.68B	1.09B	186.34%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 16, 2026

Data Sources Report a data error